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ABSTRACT
Objectives: Patient-reported health status questionnaires intend to assess
illness and therapy from the patients’ perspective. To provide fair and valid
assessments, they should be equally relevant to major subsets of respon-
dents. Furthermore, disease-speciﬁc measures are assumed to be perceived
as more relevant than generic ones. This study assessed these assumptions
among people with Parkinson’s disease.
Methods: Cross-sectional data from 202 people with Parkinson’s disease
(54% men; mean age, 70) were analyzed regarding patient-rated relevance
and predictors of patient-rated poor relevance of two generic [the 36-item
Short Form Health Survey (SF-36) and Nottingham Health Proﬁle (NHP)]
and one disease-speciﬁc [Parkinson’s Disease Questionnaire (PDQ-39)]
health status questionnaire.
Results: There were no differences in relevance ratings across the ques-
tionnaires. Poorer overall quality of life [odds ratio (OR), 2.459] and
mental health (OR, 1.023) were associated with poorer patient-rated
relevance of the SF-36, and higher age was associated with poorer patient-
rated relevance of the PDQ-39 (OR, 1.040). No signiﬁcant predictors were
found for the NHP.
Conclusions: The PDQ-39 failed to meet the assumption that disease-
speciﬁc scales are more relevant than generic ones. Nevertheless, the most
important implication of this study is an ethical one. Because the relevance
of the SF-36 and PDQ-39 is perceived as poorer by those who fare least
well and by older people, these scales may not reﬂect the perspectives of
these groups. This challenges bioethical principles and threatens scientiﬁc
validity. Perceived relevance of patient-centered outcomes needs to be
considered, or the voice of vulnerable groups may be silenced, fair infer-
ences prohibited, and opportunities for improved care lost.
Keywords: clinical research, ethics, outcomes research, Parkinson’s
disease, quality of life.
Introduction
Scientiﬁc validity is a main ethical prerequisite in clinical
research, which typically is considered in terms of study design,
statistical power, data analyses, and related aspects [1]. Never-
theless, one aspect of scientiﬁc validity that has received relatively
limited bioethical attention is that related to the outcome mea-
sures used in clinical studies.
Patient-reported outcome measures (PROs) intend to assess
the impact of illness and therapy from the patients’ perspective
and have gained increasing importance in clinical research and
practice [2–4]. In addition to the need to be psychometrically
reliable and valid representations of the variables they intend to
measure, there is also an implicit need for such measures to be
relevant to those who respond to them [3,5,6]. If they are not
equally relevant to major respondent subgroups, they are
unlikely to represent truly valid assessments of patients’ perspec-
tives and may instead discriminate against those to whom they
are less relevant [5,7]. This would threaten not only scientiﬁc
validity but also basic bioethical principles [7–11].
Health status questionnaires can broadly be classiﬁed as
generic or disease speciﬁc [12]. Generic questionnaires are broad
in scope and intended for use across a wide range of populations.
Consequently, however, they may also lack relevance to people
with a particular condition. Disease-speciﬁc tools, on the other
hand, are intended to capture aspects that are of particular
relevance to speciﬁc diagnostic groups and are therefore assumed
to be more relevant than generic ones [6,12].
Here we assessed the extent to which such assumptions are
met among people with Parkinson’s disease (PD). Speciﬁcally, we
sought to answer two questions: 1) Is a disease-speciﬁc health
status questionnaire perceived as more relevant than generic
ones? and 2) Are any major patient characteristics associated
with perceiving such questionnaires as less relevant?
Methods
Patients and Data Collection
Self-reported postal survey data from 202 people with neurolo-
gist diagnosed PD (response rate, 81%) receiving care at a
Swedish university hospital was used [13]. The survey was con-
ducted to assess the relevance and measurement properties of
commonly used patient-reported health status questionnaires.
Survey response was interpreted as consent to participate. The
study was approved by the local research ethics committee.
Assessments
The Nottingham Health Proﬁle (NHP) [14] comprises 38 items
representing six sections (Emotional Reactions, Sleep, Energy,
Pain, Physical Mobility, and Social Isolation). Embedded in the
questionnaire is also the NHP index of Distress (NHPD), a
measure of illness-related distress (score range, 0–24; 0 = less
distress) [15]. The 36-item Short Form Health Survey (SF-36)
[16] comprises 36 items representing eight domains (Physical
Functioning, Role-Physical, Bodily Pain, General Health, Vital-
ity, Social Functioning, Role-Emotional, and Mental Health). In
addition, summary measures of physical and mental health,
derived from the eight SF-36 domain scores, have been suggested
[16]. The Parkinson’s Disease Questionnaire (PDQ-39) [17] is a
39-item questionnaire assumed to represent eight domains
(Mobility, Activities of Daily Living, Emotional Well-Being,
Stigma, Social Support, Cognitions, Communication, and Bodily
Discomfort) that can be summarized into an overall score, the
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PDQ-39 Summary Index (PDQ-39SI; score range, 0–100;
0 = better). The order of the three questionnaires was random-
ized among respondents.
After responding to each questionnaire, participants were
asked to rate how relevant they perceived its content was to them
(“Please indicate how relevant you perceived that the contents of
this questionnaire were to you”). Relevance ratings were made
on a 10-grade numerical rating scale anchored by “not at all
relevant; worst possible” (1) and “extremely relevant; best
possible” (10).
Patients also rated their perceived overall quality of life (QoL)
(“Everything taken together, not only your health, how do you
perceive your quality of life?”) on a 10-grade numerical rating
scale anchored by “worst imaginable quality of life” (1) and
“best imaginable quality of life” (10). In addition, data regarding
patients’ perceived PD severity (rated as “mild”, “moderate” or
“severe”) [18], disease duration, motor complications, and
Hoehn & Yahr (HY) stages of PD [19] were collected.
Analyses
Data were analyzed by using SPSS version 14 (SPSS Inc.,
Chicago, IL). The alpha level of signiﬁcance was set at 0.05
(two-tailed). Variables were checked regarding assumptions
underlying parametric and nonparametric statistics and were
described and analyzed accordingly. Because of low numbers
of people in HY stages I (n = 9) and V (n = 27), these data were
collapsed into mild (HY stages I + II; n = 57), moderate (HY
stage III; n = 69), and advanced (HY stages IV + V; n = 76) PD.
Differences in relevance ratings across the three question-
naires were analyzed by Kruskal–Wallis test. To identify poten-
tial predictors of poorer patient-rated relevance, clinical and
demographic variables were analyzed by using bivariate (Spear-
man correlations, Mann–Whitney U- and Kruskal–Wallis tests)
and multiple regression analyses with the respective relevance
rating as dependent variables. To assess whether patients’ scores
according to the respective scales were associated with their
perceived relevance of the same questionnaire, summary scores
from the respective questionnaires were also entered into the
analyses. That is, the NHPD was added as an independent vari-
able when assessing predictors of poorer perceived relevance
of the NHP, and the PDQ-39SI was added to the analysis of
the PDQ-39. For the SF-36, the Physical Functioning (PF) and
Mental Health (MH) domain scores (score range, 0–100;
100 = better) were used instead of its physical and mental
summary measures because these have not been found valid in
neurological disorders, including PD [13,20].
Because of heteroskedasticity and non-normally distributed
residuals in linear regression, we used logistic regression. In
these analyses, the dependent variables (relevance ratings) were
dichotomized with the lowest third of relevance ratings (iden-
tiﬁed by the 33rd percentile) coded as 1 (poorer perceived rel-
evance) and others coded as 0. Similarly, ratings of perceived
overall QoL were also dichotomized by the 33rd percentile,
with the lowest third of QoL ratings coded as 1 (poorer overall
QoL) and others as 0. Perceived PD severity and collapsed HY
stages were entered as dummy variables with “mild” perceived
PD severity and HY stages I + II as reference categories. To
facilitate interpretation, PF and MH scores were reversed (i.e.,
0 = better) before being entered into the regression model. For
47 respondents (23.3%), the Social Support domain of the
PDQ-39 could not be scored because of missing item responses.
Therefore, these domain values were imputed by using the rec-
ommended algorithm [21] before calculating PDQ-39SI scores.
All regression models controlled for disease duration and their
goodness-of-ﬁt were assessed with the Hosmer–Lemeshow test,
which should yield a P-value of >0.05 to support adequate ﬁt.
Results
Table 1 summarizes patient characteristics and summary scores
on the respective questionnaires. Relevance ratings of the PDQ-
39, SF-36 and NHP did not differ signiﬁcantly across the three
questionnaires (Fig. 1).
There were signiﬁcant correlations between age and relevance
ratings of the PDQ-39 and between overall QoL and relevance
ratings of all three questionnaires (Table 2). There were signiﬁ-
cant differences in relevance ratings of the SF-36 across patients’
perceived PD severities and between dyskinetic and nondyski-
netic patients (Table 3). Relevance ratings did not differ between
sexes or across collapsed HY stages (Table 3).
Logistic regression models with dichotomized relevance
ratings as dependent variables identiﬁed signiﬁcant predictors for
two questionnaires (Table 4). Poorer overall QoL and MH were
signiﬁcantly associated with perceiving the SF-36 as less relevant,
whereas higher age was associated with perceiving the PDQ-39
as less relevant. No signiﬁcant predictors were identiﬁed for
perceiving the NHP as less relevant.
Discussion
This study assessed and compared patient-perceived relevance of
the contents of common generic (NHP and SF-36) and disease-
speciﬁc (PDQ-39) health status questionnaires among people
with PD. On average, all assessed instruments appeared to
exhibit reasonable levels of perceived relevance, because two-
thirds of respondents gave ratings of 6 to 7 or above. Never-
theless, in the case of the PDQ-39, data did not support the
assumption that disease-speciﬁc instruments are perceived as
more relevant than generic ones. Furthermore, people with
poorer overall QoL and those with poorer MH were more likely
to perceive the SF-36 because less relevant and older age was
associated with poorer perceived relevance of the PDQ-39.
Table 1 Sample characteristics (n = 202)
Sex (men/women) 108 (53.5)/94 (46.5)*
Age (years) 69.8 (10.0; 34–90)†
Disease duration (years) 8.7 (6.6;0.5–28)†
Hoehn & Yahr stage of disease§ III (II, IV; I–V)‡





Overall quality of life# 6 (5, 7; 0–10)‡
NHP index of Distress** 4 (1, 9; 0–22)‡
Physical Functioning (SF-36)†† 55 (25, 75; 0–100)‡
Mental Health (SF-36)†† 68 (56, 84; 0–100)‡
PDQ-39 Summary Index‡‡ 32.7 (21.1, 43.8; 0–79.8)‡
*n (%).
†Mean (standard deviation; min–max).
‡Median (q1, q3; min–max).
§From clinic visits within about 9 months of the postal survey, as assessed for the “off ” phase
(i.e., periods of poor drug response and increased PD-related disability). Range, I–V (I =mild
unilateral disease; II = bilateral disease without postural impairment; III = bilateral disease
with postural impairment, moderate disability; IV = severe disability, still able to walk and
stand unassisted;V = conﬁned to bed or wheelchair unless aided).
||Data from 11 people are missing.
¶Self-reported as present or absent.
#Range, 0–10 (10 = best imaginable).
**Range, 0–24 (0 = less distress).
††Range, 0–100 (100 = better).
‡‡Range, 0–100 (0 = better).
NHP, the Nottingham Health Proﬁle; PDQ-39, the 39-item Parkinson’s Disease Question-
naire; SF-36, the 36-item Short-Form Health Survey.
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The extent to which PROs are acceptable to respondents has
typically been assessed by examining response rates [22,23].
While useful, the fact that people respond to a set of items does
not necessarily indicate whether or not those items are of any
particular relevance to them [24]. PROs that intend to reﬂect
highly personal constructs such as well-being and perceived
health are often used to make inferences about the quality of ill
peoples’ lives and the effectiveness of therapies. Therefore,
quality and appropriateness criteria of such scales go beyond
traditional psychometric indices of reliability and validity; when
people respond to irrelevant questions, the meaning of their
responses diminish, and validity is at stake [25].
While appearing acceptable, the relevance ratings for the
PDQ-39 would be expected to be better than those of generic
questionnaires [6,12]. Similar to these observations, studies
among people with multiple sclerosis have failed to provide clear
evidence that disease-speciﬁc health status questionnaires are
preferred over generic ones [23]. The patient-rated relevance of
the PDQ-39 in this study is also in agreement with previous
observations, which have suggested that signiﬁcant proportions
of patients ﬁnd one or several of the PDQ-39 items of limited
relevance to describe their well-being, while important areas
appear to be missing from the questionnaire [26–28]. Neverthe-
less, our data do not provide clues as to why the PDQ-39 failed
to meet expectations relative to the generic questionnaires. To
gain some insight into this, qualitative studies or item-level rel-
evance ratings comparing the PDQ-39 with generic question-
naires are needed.
Arguably, the most important implication of this study is an
ethical one relating to the use of PROs in clinical research. So far,
ethical discussions in outcomes research have mainly focused on
what outcomes to assess, issues related to resource allocation,
and the estimation of quality-adjusted life-years [10,29,30]. Con-
siderably less attention has been paid to potential ethical impli-
cations of how and for what purposes patient-reported health
status questionnaires are used in clinical research. While ethically
laudable at one level [11,30], our observations indicate that it
cannot be assumed that such scales treat all respondents equally.
Table 2 Spearman correlations with perceived relevance of patient-reported health status questionnaires
Patient-rated relevance*
NHP SF-36 PDQ-39
Age -0.046 (P = 0.535) -0.087 (P = 0.231) -0.252 (P = 0.0004)
Disease duration -0.103 (P = 0.165) -0.132 (P = 0.072) -0.134 (P = 0.067)
Overall quality of life† 0.257 (P = 0.0004) 0.346 (P < 0.0001) 0.241 (P = 0.001)
NHP index of Distress‡ -0.190 (P = 0.014) — —
Physical Functioning (SF-36)† — 0.226 (P = 0.002) —
Mental Health (SF-36)† — 0.274 (P = 0.0001) —
PDQ-39 Summary Index‡ — — -0.101 (P = 0.167)
*Range: 1 (“not at all relevant”) to 10 (“extremely relevant”).
†Higher scores = better.
‡Higher scores = worse.






















Figure 1 Box plots of patient-rated relevance of the contents of the NHP,
SF-36, and PDQ-39 among people with PD (n = 202). Relevance was rated on
a 10-grade numerical rating scale ranging from “not at all relevant” (1) to
“extremely relevant” (10). Solid horizontal lines are median values, boxes are
inter-quartile ranges (q1, q3), and error bars are ranges. Open circles are
outliers, deﬁned as values >1.5 box lengths below the 25th percentiles.There
were no signiﬁcant differences in relevance ratings across the three question-
naires (P = 0.142; Kruskal–Wallis test). NHP, the Nottingham Health Proﬁle;
SF-36, the 36-item Short-Form Health Survey; PDQ-39, the 39-item Parkinson’s
Disease Questionnaire.
Table 3 Perceived relevance of patient-reported health status question-




Male 7 (5, 8) 7 (5, 8) 7 (6, 8)
Female 7 (6, 8) 7 (6, 8) 8 (6, 8)
Hoehn & Yahr
Stages I + II 7 (5, 9) 7 (6, 9) 8 (6, 9)
Stage III 7 (6, 8) 7 (5.5, 8) 7 (6, 8)
Stages IV + V 7 (6, 8) 7 (5, 8) 7 (6, 8)
Perceived PD severity
Mild 8 (5.75, 9) 8 (6, 9)† 8 (6, 9)
Moderate 7 (6, 8) 7 (6, 8)† 8 (6, 8)
Severe 7 (5.25, 8) 6 (4.75, 7.25)† 7 (6, 8)
Motor complications
Dyskinetic 7 (5, 8) 7 (5, 8)‡ 8 (6, 8)
Nondyskinetic 7 (6, 9) 7 (6, 8.5)‡ 8 (6, 8)
*Range: 1 (“not at all relevant”) to 10 (“extremely relevant”). Data are median (q1, q3).
†P = 0.009 (Kruskal–Wallis test) for differences across patients perceiving their PD as Mild,
Moderate, and Severe. Bonferroni corrected post hoc Mann–Whitney U-tests revealed
signiﬁcantly higher patient-rated relevance of the SF-36 among patients who perceived the
severity of their PD as Mild compared with patients who perceived it as Severe (P = 0.009).
There were no signiﬁcant differences between patients perceiving their PD as Mild and
Moderate (P = 0.615) or Moderate and Severe (P = 0.054).
‡P = 0.014 (Mann–Whitney U-test); nondyskinetic patients rated the SF-36 as more relevant
than dyskinetic patients.
NHP, the Nottingham Health Proﬁle; PDQ-39, the 39-item Parkinson’s Disease Question-
naire; SF-36, the 36-item Short-Form Health Survey.
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Using PROs such as those studied here implies an interest in the
impact of illness and therapy from the patients’ perspective. In
general, it also appears reasonable to assume that studies using
such end points are particularly concerned about those people
who fare least well. Notably, however, it was exactly to this group
of people with PD that the SF-36was of least relevance. This poses
challenges on the scientiﬁc validity and, hence, ethics of its use for
this purpose [1,5,7,9]. Similarly, an association was found
between older age and poorer perceived relevance of the PDQ-39.
Bioethics has emphasized the patient’s point of view by its call
for autonomy. In terms of outcomes research, this is supposed
to be realized through “patient-centered” outcome measures
by which patients’ perspectives are sought to provide them with
a voice and to guide decisions regarding the effectiveness of
therapy [2,5,10,11]. Nevertheless, if the questions asked prevent
those who fare least well from making their voices heard because
of poor relevance (such as implied in the case of the SF-36 here),
those people’s perspectives will not be taken into account to the
same extent as those of others. This can potentially challenge not
only autonomy but also other bioethical principles [9–11]. As a
result of not having the same meaning or relevance among
various subgroups of people, such outcome measures may cause
misleading inferences. This has potential implications for indi-
vidual patient care because clinical trial outcomes are the basis
for evidence-based practice.
Overall QoL correlated positively with the relevance ratings
of all three studied questionnaires. This suggests that people with
better overall QoL tend to consider their contents as more rel-
evant than those with poorer overall QoL. We have previously
found NHP and PDQ-39 scores to be no more associated with
overall QoL in PD than, e.g., duration of disease [18]. Similarly,
the contents of the PDQ-39 have been found to correspond
poorly with areas nominated as important QoL domains by
people with PD [31], and other investigators have reported that
some respondents were uncertain whether the PDQ-39 would
reﬂect their experiences [28]. Similar observations have also been
reported from studies in, e.g., multiple sclerosis and amyotrophic
lateral sclerosis [23,32]. This is not surprising because health
status questionnaires, such as those studied here [14,16,17] were
not developed to measure QoL, although they often have been
used for this purpose. Therefore, their tendency to discriminate
against those who consider their overall QoL to be most com-
promised appears to render their use as QoL measures not only
scientiﬁcally unsound but also ethically questionable [1,4,5,7].
In contrast to our ﬁndings, studies have suggested that the
SF-36 is less suitable among older people because of compro-
mised relevance [33]. This discrepancy may be explained by the
age distribution in PD. We did, however, ﬁnd an association
between older age and poorer perceived relevance of the PDQ-
39, suggesting decreasing questionnaire validity with increasing
age. This ﬁnding may relate to the characteristics of the people
surveyed when developing the PDQ-39. Nevertheless, no demo-
graphic information is available for the sample interviewed to
generate PDQ-39 items [17].
There are a number of limitations to this study. The sample
was not community based or randomly selected, which limits
the generalizability of results. Nevertheless, it represents a wide
range of disease severity and duration and has similar character-
istics to those reported from large-scale randomized studies [34].
Secondly, only crude single-item scales were used to measure
relevance and overall QoL. Nevertheless, although more detailed
item-level relevance ratings probably would have been prefer-
able, this was not considered feasible given the current study
design, and single-item QoL measures have been found useful
[35]. Furthermore, it can be questioned whether people are able
to distinguish between as many as 10 different levels of relevance
or QoL. Thirdly, a number of other factors not studied here could
inﬂuence the relevance ratings. As the study was conducted in
one country it is also possible that cultural aspects may have
inﬂuenced ﬁndings, although all three questionnaires have been
rigorously translated and evaluated [14,27,36]. Finally, only one
disorder and a limited (albeit commonly used) number of ques-
tionnaires were considered. This precludes generalizations to
other patient groups and questionnaires. Additional studies in
other patient populations using other questionnaires are there-
fore warranted. It would also be of interest for future studies to
consider the potential relationship between qualitative aspects
such as perceived relevance and content validity on one hand and
quantitative indices of differential item functioning on the other.
Importantly, however, this empirical assessment of associa-
tions between patient characteristics and the perceived relevance
of patient-reported health status questionnaires has identiﬁed an
issue of utmost saliency for clinical research and practice that
needs to be taken into account to ensure scientiﬁc and ethical
soundness of research. This has implications for clinicians, inves-
tigators, funding bodies, and ethics committees within an area of
recognized and growing eminency for clinical research [4]. We
propose that evaluations such as those conducted here should
complement assessments of measurement properties of scales
intended to reﬂect patient-centered outcomes such as perceived
well-being, health, or QoL. Otherwise, the voice of vulnerable
patients may be silenced, fair inferences regarding effectiveness of
therapy prohibited, and opportunities to improve patient care
lost.
Table 4 Predictors of poor perceived relevance of contents in patient-reported health status questionnaires*
Dependent variable† Predictors‡ Odds Ratio (95% CI) P-value Goodness-of-ﬁt (P-value)§
NHP|| —** — — —
SF-36¶ Poor overall QoL 2.459 (1.074, 5.630) 0.033 0.729
Poorer mental health 1.023 (1.004, 1.044) 0.020
PDQ-39# Higher age 1.040 (1.004, 1.077) 0.031 0.301
*As identiﬁed by backward stepwise (likelihood-ratio) logistic regressions.
†Relevance ratings dichotomized by the 33rd percentile (i.e., scores of 5 for the NHP and SF-36, and of 6 for the PDQ-39) with the poorest third coded as 1 (poor perceived relevance).
‡Independent variables entered into all three analyses were sex (0 = female; 1 =male), age (years), PD duration (years); collapsed HY stages (with HY stages I + II as the reference category),
perceived overall PD severity (with “mild” as the reference category), dyskinesias (0 = absent; 1 = present), and overall perceived QoL dichotomized by the 33rd percentile (i.e., a score of 4)
with the poorest third coded as 1 (poor overall QoL).
§Hosmer–Lemeshow test for goodness-of-ﬁt.
||NHP index of Distress entered as independent variable.
¶Physical Functioning and Mental Health domain scores entered as independent variables.
#PDQ-39 Summary Index entered as independent predictor.
**None of the entered independent variables were signiﬁcantly associated with poor relevance ratings of the NHP.
CI, conﬁdence interval; NHP, the Nottingham Health Proﬁle; HY, Hoehn &Yahr; SF-36, the 36-item Short-Form Health Survey; PDQ-39, the 39-item Parkinson’s Disease Questionnaire; QoL,
overall perceived quality of life.
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